Pharma competitive intelligence that shows what each rival move means for you.

Pharma competitive intelligence is the ongoing collection and analysis of what rival drugs and the companies behind them are doing, from trials and evidence to messaging and launches. Beyond monitoring, the work explains what each competitor move means for one brand and how to respond before the market shifts. Nextyn adds interviews with HCPs, payers and priority accounts in the United States and Europe, so each signal comes with its likely effect on prescribing and access.

A Nextyn competitor and entrant tracker delivers three outputs: a tracker of competitors and new entrants, an implications brief for every key event, and positioning and priority recommendations. Each output pairs public signals with primary interviews, so the client receives implications rather than a feed to sort through:

• Competitor and entrant tracker: trials, evidence, messaging and launch activity for the agreed competitor set
• Implications brief: what each readout, launch or claim changes for the client's brand
• Recommendations: the positioning, messaging and priority changes the signals support

Nextyn interviews the four groups who see competitor moves first-hand: prescribing HCPs, key opinion leaders, payers and priority accounts. Their views show how a rival claim, readout or launch is landing with the people who decide uptake, before it shows up in prescribing data:

• Prescribing HCPs, on how competitor messages and evidence are received
• Key opinion leaders, on how new trial data changes treatment thinking
• Payers, on how a new entrant shifts access and price expectations
• Priority accounts, on competitor service, contracting and formulary activity

Nextyn runs pharma competitive intelligence in the United States, the United Kingdom, Germany, France, Italy and Spain, among other markets. The competitor set and markets are agreed at scoping and can be revised as the landscape changes, because a rival's launch sequence rarely matches the client's own. Recent Nextyn work includes interviews with HCPs, payers and priority accounts in Europe that compared competing specialty-care brands on clinical confidence, access, service and messaging.

Nextyn recommends starting pharma competitive intelligence before a competitor readout, launch or label change that the brand will have to answer. Tracking set up in advance means the implications brief and response are ready when the event lands, instead of after the market has moved. There are three other triggers for tracking: a new entrant in the class, a loss of share without a clear cause, and the run-up to the client's own launch.

A Nextyn competitive intelligence project runs in four steps, from brief to read-out, and nothing is commissioned until the client approves the plan. The client sees the competitor set, method and price before any tracking starts, and reads every interview with the Nextyn team at each read-out.

1. Submit the brief: the brand, the competitors and entrants to watch, the markets and the events that matter.
2. Receive a plan within 48 hours: the signals to track, who Nextyn will interview, how, and what the work costs.
3. Approve the plan: tracking and fieldwork start only after sign-off.
4. Review the read-out: every interview read together, showing where stakeholders agree, where they conflict and what is still open.

Nextyn sends a research plan within 48 hours of receiving the brief, stating what will be tracked, who will be interviewed, how, and what the work costs. The plan sets the length of the first read and the update schedule, tied to the events that matter, such as trial readouts and launches. Nothing is commissioned until the client approves that plan and its price.

Nextyn's pharma competitive intelligence interprets competitor moves for one brand, using interviews with HCPs, payers and accounts, while a competitive intelligence database collects signals across a market for every subscriber. The database shows what happened, and the interviews show how prescribers and payers are reacting and what the brand should do next.